QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lisata-therapeutics-releseass-preliminary-results-from-pancreatic-ductal-adenocarcinoma-cohort-in-phase-12a-cendifox-trial-showing-certepetide-can-enhance-the-effectiveness-of-standard-of-care-chemotherapy-in-pancreatic-cancer

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Scie...

 hc-wainwright--co-reiterates-buy-on-lisata-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 p...

 lisata-therapeutics-q2-eps-054-beats-065-estimate-sales-7000k

Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $...

 brookline-capital-maintains-buy-on-lisata-therapeutics-raises-price-target-to-32

Brookline Capital maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $20 to $32.

 us-patent-and-trademark-office-issues-lisata-therapeutics-composition-of-matter-patent-for-certepetide-through-march-2040-with-opportunity-for-patent-term-extension

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extensionThis p...

 agitg-nhmrc-clinical-trials-centre-at-university-of-sydney-and-lisata-therapeutics-announce-preliminary-cohort-b-data-from-ascend-phase-2b-trial-in-metastatic-pancreatic-cancer

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentiallyPositive signal i...

 lisata-therapeutics-and-gatc-health-announce-strategic-alliance-to-accelerate-and-improve-success-rate-of-traditional-drug-development-process

Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® p...

 lisata-enters-into-research-license-with-catalent-to-evaluate-efficacy-of-lisatas-irgd-cyclic-peptide-product-candidate-certepetide-as-payload-used-in-smartag-adc-dual-payload-tech-platform

BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "C...

 lisata-therapeutics-and-gatc-health-begin-strategic-collaboration-to-use-ai-to-derisk-and-accelerate-drug-development

Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technol...

 lisata-therapeutics-q4-gaap-eps-055-beats-079-estimate

Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...

 lisata-and-warpnine-announces-interim-phase-1b2a-results-for-certepetide-in-pancreatic-cancer-56-show-partial-response-after-4-cycles-with-up-to-90-reduction-in-ca19-9-levels-results-to-be-presented-at-2025-asco-gi-symposium

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION